The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Open accessAbstract
BACKGROUND: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. OBJECTIVES: This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. METHODS: Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. RESULTS: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. CONCLUSIONS: In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationSchwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Self-citationShared Frailty Models for Recurrent Events and a Terminal Event
Liu, L., Wolfe, R. A., & Huang, X. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00225.x · Cited by 340
Rondeau, V., Mathoulin-Pelissier, S., Jacqmin-Gadda, H., Brouste, V., & Soubeyran, P. (2006) · Biostatistics · doi:10.1093/biostatistics/kxl043 · Cited by 211
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., & Braunwald, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.005 · Cited by 175
Television Viewing, Computer Use, Time Driving and All‐Cause Mortality: The SUN Cohort
Basterra‐Gortari, F. J., Bes‐Rastrollo, M., Gea, A., Núñez-Córdoba, J. M., Toledo, E., & Martínez‐González, M. Á. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000864 · Cited by 98
Tikkanen, M., Szarek, M., Fayyad, R., Holme, I., Cater, N., Faergeman, O., Kastelein, J., Olsson, A., Larsen, M., Lindahl, C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.035 · Cited by 76
Self-citationLaRosa, J. C., DEEDWANIA, P. C., Shepherd, J., WENGER, N. K., Greten, H., DeMicco, D. A., & Breazna, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 66
Cited by
Sorted by citations
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Self-citationFeinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., & Post, W. S. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 673
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra‐Ojeda, S., Vila, J. M., Aldasoro, M., Víctor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 651
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259
Self-citation2020 Clinical practice guidelines for Stable coronary artery disease
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4076 · Cited by 313
Szarek, M. J., Bittner, V., Aylward, P. E., Baccara‐Dinet, M. T., Bhatt, D. L., Díaz, R., Fras, Z., Goodman, S. G., Halvorsen, S., Harrington, R. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa649 · Cited by 226
Self-citationEverett, B. M., MacFadyen, J. G., Thuren, T. Y., Libby, P., Glynn, R. J., & Ridker, P. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.011 · Cited by 238
Myocardial Infarction—From Atherosclerosis to Thrombosis
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 208
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
Gallego-Colon, E., Daum, A., & Yosefy, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173114 · Cited by 156
Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Brégeault, M.-F., Dalby, A. J., Díaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038840 · Cited by 153
Self-citationAlleyne, C., Amin, R. P., Bhatt, B., Bianchi, E., Blain, J. C., Boyer, N. C., Branca, D., Embrey, M. W., Ha, S., Jette, K. M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01084 · Cited by 138
Enas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.03.004 · Cited by 128
Packard, C. J., Chapman, M. J., Sibartie, M., Laufs, U., & Masana, L. (2021) · Heart · doi:10.1136/heartjnl-2020-318760 · Cited by 114
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
Singh, A., Gupta, A., Collins, B., Qamar, A., Monda, K. L., Biery, D. W., López, J. A. G., de Ferranti, S. D., Plutzky, J., Cannon, C. P., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.059 · Cited by 108
Self-citationEffect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
Myers, K. D., Farboodi, N., Mwamburi, M., Howard, W. H. R., Staszak, D., Gidding, S. S., Baum, S. J., Wilemon, K. A., & Rader, D. J. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005404 · Cited by 96
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni‐Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 91
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
Self-citationMcGuire, D. K., Zinman, B., Inzucchi, S. E., Wanner, C., FITCHETT, D. H., Anker, S. D., Pocock, S., Kaspers, S., George, J. T., von Eynatten, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30344-2 · Cited by 76
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Goodman, S. G., Aylward, P. E., Szarek, M. J., Chumburidze, V., Bhatt, D. L., Bittner, V., Díaz, R., Edelberg, J. M., Hanotin, C., Harrington, R. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.015 · Cited by 71
Self-citationDrexel, H., Coats, A. J. S., Spoletini, I., Bilato, C., Mollace, V., Filardi, P. P., & Rosano, G. M. C. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz079 · Cited by 71
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 69
Jhund, P. S., Ponikowski, P. P., Docherty, K. F., Gasparyan, S. B., Böhm, M., Chiang, C., Desai, A. S., Howlett, J. G., Kitakaze, M., Petrie, M. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053659 · Cited by 71
Self-citationEffects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
White, H. D., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Edelberg, J. M., Ērglis, A., Goodman, S. G., Hanotin, C., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz299 · Cited by 65
Self-citationCost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M. J., Bittner, V., Díaz, R., Goodman, S. G., Harrington, R. A., Higuchi, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.029 · Cited by 63
Self-citationSzarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066398 · Cited by 61
Self-citationRecent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 63
Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 58
Jacobson, T. A., Cheeley, M. K., Jones, P. H., Forge, R. L., Maki, K. C., López, J. A. G., Xiang, P., Bushnell, D. M., Martin, M. L., & Cohen, J. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.011 · Cited by 57
Bauersachs, R. M., Szarek, M. J., Brodmann, M., Gudz, I., Debus, E. S., Nehler, M. R., Anand, S. S., Patel, M. R., Hess, C. N., Capell, W. H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.003 · Cited by 60
Self-citationGuo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., & Zheng, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30025 · Cited by 57
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 59
Feng, Z., Li, X., Tong, W. K., He, Q., Zhu, X. L., Xiang, X., & Tang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894685 · Cited by 53
Peng, J., Liu, M., Jin, J., Cao, Y., Guo, Y., Wu, N., Zhu, C., Dong, Q., Sun, J., Xu, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01142-0 · Cited by 54
Schwartz, G. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Bujas‐Bobanovic, M., Díaz, R., Fazio, S., Fras, Z., Goodman, S. G., Harrington, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad144 · Cited by 51
Self-citationmRNA Display Reaches for the Clinic with New PCSK9 Inhibitor
Iskandar, S. E., & Bowers, A. A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00319 · Cited by 52
Low-Density Lipoprotein Cholesterol
Cannon, C. P. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.033 · Cited by 49
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories
Szarek, M. J., Amarenco, P., Callahan, A. S., III, DeMicco, D. A., Fayyad, R. S., Goldstein, L. B., Laskey, R. E., Sillesen, H. H., & Welch, K. M. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.015 · Cited by 43
Self-citationImpact of Bempedoic Acid on Total Cardiovascular Events
Nicholls, S. J., Nelson, A. J., Lincoff, A. M., Brennan, D. M., Ray, K. K., Cho, L., Menon, V., Li, N., Bloedon, L. T., & Nissen, S. E. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5155 · Cited by 50
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 44
Ostadal, P., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V., Chua, T., Díaz, R., Goodman, S. G., Huo, Y., Jukema, J. W., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00043-2 · Cited by 40
Self-citationAscaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.002 · Cited by 42
Surf4, cargo trafficking, lipid metabolism, and therapeutic implications
Shen, Y., Gu, H.-M., Qin, S., & Zhang, D. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac063 · Cited by 37
Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01179-1 · Cited by 35
Schremmer, J., Busch, L., Baasen, S., Heinen, Y., Sansone, R., Heiß, C., Kelm, M., & Stern, M. E. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104513 · Cited by 34
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Cao, Y., Jin, J., Sun, D., Liu, H., Guo, Y., Wu, N., Xu, R., Zhu, C., Dong, Q., Sun, J., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2123-9 · Cited by 30
Puri, R., Mehta, V., Duell, P. B., Nair, D. R., Mohan, J. C., Yusuf, J., Dalal, J. J., Mishra, S., Kasliwal, R. R., Agarwal, R., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.006 · Cited by 30
The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion
Deng, S., Shen, Y., Gu, H.-M., Guo, S., Wu, S.-R., & Zhang, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158660 · Cited by 31
Cordero, A., Rodríguez‐Mañero, M., Fácila, L., Fernández-Olmo, M. R., Gómez-Martínez, M. J., Valle, A., Castellano, J. M., Toro, M. M., Seijas‐Amigo, J., Vicedo-López, Á., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00557-6 · Cited by 30
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
Sea Change for Marine Omega-3s
O'Keefe, E. L., Harris, W. S., DiNicolantonio, J. J., Elagizi, A., Milani, R. V., Lavie, C. J., & O'Keefe, J. H. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.027 · Cited by 28
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.06.001 · Cited by 27
Xu, M., Zhu, X., Wu, J., Zhang, Y., Zhao, D., Wang, X., Ding, Y., Cao, Y., Li, C., Hu, W. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02208-w · Cited by 27
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 27
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 27
Self-citationImmunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV
Kettelhut, A., Bowman, E., & Funderburg, N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00509-y · Cited by 24
Alings, M., Descamps, O. S., Guillon, B., Leósdóttir, M., Maggioni, A. P., Recasens, L., Speidl, W. S., Tripodi, R., Landmesser, U., Catapano, A. L., et al. (2020) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2021.01.010 · Cited by 24
Self-citationLopez-Sendon, J. L., Cyr, D. D., Mark, D. B., Bangalore, S., Huang, Z., White, H. D., Alexander, K. P., Li, J., Rajesh, G. N., Demkow, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab509 · Cited by 24
Self-citationCordero, A., Rodríguez‐Mañero, M., Bertomeu‐González, V., García‐Acuña, J. M., Baluja, A., Agra-Bermejo, R., Álvarez, B. Á., Cid, B., Zuazola, P., & González‐Juanatey, J. R. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.03.020 · Cited by 23
Szarek, M. J., Steg, P. G., DiCenso, D., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Gotcheva, N. N., Jukema, J. W., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005858 · Cited by 23
Self-citationAdherence to statin therapy favours survival of patients with symptomatic peripheral artery disease
Dopheide, J. F., Veit, J., Ramadani, H., Adam, L., Papac, L., Vonbank, A., Kaspar, M., Rastan, A., Baumgärtner, I., & Drexel, H. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz081 · Cited by 23
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 28
Ministrini, S., & Carbone, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210810150940 · Cited by 23
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Current development of bicyclic peptides
Feng, D., Liu, L., Shi, Y., Du, P., Xu, S., Zhu, Z., Xu, J., & Yao, H. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.108026 · Cited by 22
Angoulvant, D., Granjeon-Noriot, S., Amarenco, P., Bastien, A., Béchet, E., Boccara, F., Boissel, J., Cariou, B., Courcelles, E., Diatchenko, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae254 · Cited by 26
Self-citationEmerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 21
Drug intervention as an emerging concept for secondary prevention in patients with coronary disease
Minami, Y., Ako, J., Tsujita, K., Yokoi, H., Ikari, Y., Morino, Y., Kobayashi, Y., & Kozuma, K. (2024) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-024-00994-7 · Cited by 21
Eurasian Guidelines for the diagnostics and management of stable coronary artery disease (2020-2021)
IuA, K., Барбараш, О. Л., Boshchenko, A. A., Кашталап, В. В., Kukharchuk, V. V., Миронов, В. М., Панченко, Е. П., Ruda, M. M., Samko, A. N., Соболева, Г. Н., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-3-54-93 · Cited by 22
Chen, T., Wang, Z., Xie, J., Xiao, S., Li, W., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.033 · Cited by 20
Cannon, C. P., Khan, I., Klimchak, A. C., Sanchez, R. J., Sasiela, W. J., Massaro, J. M., D’Agostino, R. B., & Reynolds, M. R. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.06.005 · Cited by 20
Drexel, H., Rosano, G. M. C., Lewis, B. S., Huber, K., Vonbank, A., Dopheide, J. F., MADER, A., Niessner, A., Savarese, G., Waßmann, S., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz029 · Cited by 20
Schwartz, G. G., & Giugliano, R. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000830 · Cited by 19
Self-citationNew Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
Hutton, M., Frazer, M., Lin, A., Patel, S., & Misra, A. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.08.015 · Cited by 17
Colivicchi, F., Fusco, S. A. D., Scicchitano, P., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., Aspromonte, N., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001108 · Cited by 18
Risk factor reduction in type 2 diabetes demands a multifactorial approach
Rydén, L., Ferrannini, G., & Mellbin, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319872015 · Cited by 17
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Wang, Z., Chen, J., Zeng, Z., Zhang, Q., Du, G., Guo, X., & Wei, Y. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00450-3 · Cited by 16
PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability
Enkhmaa, B., Kim, K., Zhang, W., Prakash, N., Truax, K., Anuurad, E., & Berglund, L. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa073 · Cited by 15
Parthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15
Frasco, P. E., Mathur, A. K., Chang, Y.-H. H., Alvord, J. M., Poterack, K. A., Khurmi, N. S., Bauer, I., & Aqel, B. A. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.10.007 · Cited by 14
PCSK9 inhibition 2018: riding a new wave of coronary prevention
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Clinical Science · doi:10.1042/cs20171300 · Cited by 13
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 14
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
Gibson, C. M., Chi, G., Duffy, D., Bahit, M. C., White, H. D., Korjian, S., Alexander, J. H., Lincoff, A. M., Anschuetz, G., Girgis, I. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.001 · Cited by 13
Self-citationAnnemans, L., Stock, J. K., & Chapman, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.005 · Cited by 12
The impact of the PCSK-9/VLDL-Receptor axis on inflammatory cell polarization
Barcena, M. L., Estepa, M., Marx, L., Breiter, A., Haritonow, N., & Stawowy, P. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156077 · Cited by 12
Synthesis of a Complex and Highly Potent PCSK9 Inhibitor
Kuethe, J. T., Lee, J., Thaisrivongs, D. A., Yasuda, N., Pollack, S. R., Leone, J. F., DaSilva, J., Biba, M., Tsay, F., Regalado, E. L., et al. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c01635 · Cited by 11
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Davidson, M. H., Hsieh, A., Dicklin, M. R., & Maki, K. C. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.12.005 · Cited by 14
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 15
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Ferri, N., Greco, M. F., Corsini, A., & Ruscica, M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa063 · Cited by 10
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
PCSK9 in Vascular Aging and Age-Related Diseases
Tan, D., Yang, X., Yang, J., Fan, G., & Xiong, G. (2025) · Aging and Disease · doi:10.14336/ad.2024.1713 · Cited by 10
Brandts, J., & Müller‐Wieland, D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0802-x · Cited by 9
Lipid-lowering agents in solid organ transplant recipients
Mickiewicz, A., Żegleń, S., Kędzierska-Kapuza, K., Heleniak, Z., Frankiewicz, A., Adamczyk, E., Wełnicki, M. T., Wawrzynowicz‐Syczewska, M., Raszeja‐Wyszomirska, J., Durlik, M., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf104 · Cited by 8
Vadhariya, A., Paranjpe, R., Essien, E. J., Johnson, M. L., Fleming, M. L., Esse, T. W., Gallardo, E., Serna, O., Choi, J., Boklage, S., et al. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.09.002 · Cited by 8
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Cordero, A., Rodríguez‐Mañero, M., Bertomeu‐González, V., García‐Acuña, J. M., Baluja, A., Agra-Bermejo, R., Álvarez, B. Á., Cid, B., Zuazola, P., & González‐Juanatey, J. R. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.03.011 · Cited by 8
Metadata
- Authors
- Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Kimura, T., Kiss, R. G., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Roe, M. T., Tricoci, P., Xavier, D., Zeiher, A. M., & Steg, P. G.
- Affiliations
- State University of New York (US)
- University of Auckland (NZ)
- University of Colorado Anschutz (US)
- Amphia Ziekenhuis (NL)
- Brigham and Women's Hospital (US)
- University of Alabama at Birmingham (US)
- Taipei Veterans General Hospital (TW)
- Sanofi (United States) (US)
- St. Michael's Hospital (CA)
- Sanofi (France) (FR)
- Stanford University (US)
- Leiden University Medical Center (NL)
- Kyoto University (JP)
- Regeneron (United States) (US)
- Duke University (US)
- Goethe University Frankfurt (DE)
- Corresponding author
- Szarek, Michael
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 73
- Issue
- 4
- Pages
- 387-396
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2900103074
- Cited by
- 173
- References
- 12
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 18 · 2023: 15 · 2022: 18 · 2021: 17 · 2020: 45 · 2019: 42
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc-nd)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion, cc-by-nc-nd)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by-nc-nd)
- Lanzhou University Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, acute coronary syndrome, ODYSSEY OUTCOMES trial, PCSK9 inhibitors, all-cause mortality, shared frailty model, high-intensity statin therapy, myocardial infarction, stroke, coronary revascularization, unstable angina, heart failure
- MeSH terms
- Aged, Antibodies, Monoclonal, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
